

Oregon Board of Naturopathic Medicine
Public Board Meeting
October 12, 2015

Present: Dwight Adkins, Board Chair; Patrick Chapman, ND, Sara Ohgushi, ND; Lissa McNiel, ND; Sheila Myers, ND, Greg Eckel, ND, Charles Wiggins and Anne Walsh, Executive Director.

The Board went into Public Session at 10:05am.

Executive Session Motions: In case **N15-07-09N, N15-08-15N, N15-09-17, and N15-09-18, P.** Chapman moved to dismiss and L. McNiel seconded the motion, all members agreed. An investigation was opened in **N15-09-19A, N15-09-20, N15-09-20, N15-09-21, N15-09-22, and N15-10-23** with a motion by P Chapman, seconded by L. McNiel.

Meeting Minutes: The minutes from the August 24, 2015 meeting were approved by unanimous vote.

Administrative Rules: The Board discussed amendments to **OAR 850-060-0226** as recommended by the FC from the September 16 meeting. These recommendations include: (8) Remove “Selective Serotonin Agonists”; (19) Change “Hormone and Synthetic Substitutes” to “Endocrine Metabolic Agents”; Add “Corticosteroids” and “Prostaglandin”; (21) Remove “except for Mifepristone” and add “not to be used as an abortifacient”; (25) Add “and Nutrients”; (26) Delete limiting language after Biologic Response Modifiers; and add “Hyaluronic Acid” and “Oxygen”

Discussion was held on the compensation received by Board members. After review of ORS 685.190 and ORS 292.495, the Board voted to increase the daily compensation in OAR 850-005-0190 to \$200 for a full day, and \$60 for less than 3 hours.

S. Myers made a motion to initiate rule-making in 850-060-0226 and 850-005-0190; S Ohgushi seconded the motion and the motion was approved.

General Business:

Formulary Council Update – P. Chapman reported on the September 16 FC meeting. The amendments to 850-060-0226 were approved after discussion. The FC is working to make sure that all the drugs listed in 850-060-0225 are classified in 850-060-0226 and then that rule (-0225) will be deleted which will reduce confusion for pharmacists and NDs. Discussion on medical marijuana was held with no decision to ask the Board to move forward with any changes in current law, the OANP will be asked to take the lead on this matter.

Opiate Prescribing – P. Chapman informed the board that the opiate prescribing information is posted on the OBNM website. If anyone has other resource links regarding opiate prescribing they should be forwarded to A. Walsh who can add them to the web site as a reference.

Legislation 2016 Session – A. Walsh and D. Adkins have discussed the 2016 legislative session regarding redefining of physician in statute. D. Adkins has spoken with some legislators who may be able to assist in trying to get this heard in the 2016 session.

The OBNM will need to make a decision on any legislative concepts they would like considered in the 2017 session and have them ready sometime in the spring (April). Further discussion will be had at the December meeting.

Injection Therapy – G. Eckel informed the board that Dr. Paul Anderson will have a session at the OANP conference in December which will go over standard of care and what the law states regarding the compounding practices.

Strategic Planning Update – no update on Strategic Planning until new members are appointed, The Board will look to set a date for a retreat at the December meeting if possible.

Directors Report: The newly hired accountant is doing a wonderful job. The 2015-2017 budget has been finalized and Ms. Walsh is just waiting on reports to finish the LAB report.

Ms. Walsh is still looking to recruit a part time investigator, but is utilizing a temporary investigator for the time being.

Renewals should be ready to open online November 1, with notice going out in the newsletter and online. The newsletter is slow getting to press this year, but should be ready and to licensees by November 1.

Miscellaneous: Inquiry: Is PICC line placement l within the scope of practice? The use of a previously placed PICC line is common in practice. There is no prohibition on NDs inserting the peripherally inserted central catheter; however, the general practice is to refer this out to a medical professional with this specialized training.

Is Artesunate within the scope of practice? Artesunate is within the scope of the naturopathic formulary. It would be listed as an anti-malarial (850-060-0226(2)(f)(B)). The formulary does not determine, except with a few drugs, the administration of a medication either the administration or purpose. The physician decides on the use of medicines as deemed medically appropriate.

Public Comment: No one was in attendance to provide public comment.

As there was no more business to discuss, the Board adjourned at 1:00pm.

Board members worked on CE after the close of the meeting.